Get started
JOHNSON & JOHNSONJOHNSON & JOHNSONJOHNSON & JOHNSON

JOHNSON & JOHNSON

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

JNJ trade ideas

JOHNSON & JOHNSON PULL BACK TO SUPPORT OF ITS TRIANGLE-LONGJ&J STOCK, AFTER BREAKS UP A TRIANGLE PATTERN IS PULLING BACK TO SUPPORT AT 137.25, WHICH GIVE A GOOD OPPORTUNITY TO ENTER . I AM EXPECTING THE STOCK HOLDS AT SUPPORT AND BOUNCE. THE INITIAL TARGET COULD BE 145, WHICH IS THE 200% OF FIBONACCI EXTENSION OF THE PREVIOUS LOW. HOWEVER, THE TRIANGLE CALL FOR A LONG TERM TARGET OF 151-152 MINIMUM. IF THE STOCK PRICE BREAKS SUPPORT DOWN FOR A GOOD MARGIN, THE STOP LOSS IS SET UP AT 134. THIS ANALYSIS IS FOR EDUCATION PURPOSES. GOOD LUCK!!!! www.tradingview.com
NYSE:JNJLong
by ralvizua
Stocks that have raised dividends for at least 25 Years11/18/17 - JNJ has been on a majestic bullish power trend since 03/09. You can't be anything but bullish long-term. If we were trying to time the market or at least get a better price, we might want to wait for a 10% pullback to the most recent pivot high of 123-126ish from August 2016. If that area of 123-126 is taken out I would be more bearish than bullish with the next lower target area of 109-113ish. As a strong fundamental company that has increased dividends every year for 54 straight years and is stable during a recession, this is a great company to own for your portfolio. Current Forward Dividend & Yield is 3.36 (2.37%).
NYSE:JNJLong
by ArtPeirce
JNJ - RiskReversal on Johnson & JohnsonThis is my first trade I post not only here, but also on my new blog (see footer) & chat here on TV. I start this group education on TV because I see how many traders could be more successful, if they only had more knowledge, how to trade by combining high probability strategies. My method is the combination of the Forks and Options. But I also trade 100% directional with the underlying, leaning on my one strategy. If you like my style, then join the ForkTrading Method chat here on TV. The chart shows you how I combine my Forks with Options. Currently I see a bounce to the downside, as price leaves the Centerline. I post a detailed description about the trade with a PNL graph on my website (see footer), so I can keep the chat as clean and lean as possible. Always appreciate your comments, questions and constructive criticism too ;-) P!
NYSE:JNJShort
by Tr8dingN3rd
It's time! This idea is being spiced up now!As a reminder: Based on 17 analysts offering 12 month price targets for JNJ in the last 3 months: The average price target is $ 147 The maximum price target is $ 165 The lowest price target is $ 110 The entry into this idea is currently at $ 144.33. What say the technical analysis methods I use? The risk management tool used here is the own-developed “Traffic Signals System” (TSS) and it will be implemented in my future analyses. The yellow circle on the 11th of October in the chart indicates a possible break-away GAP for me. The 2nd yellow circle on October 30 in the chart could be closed in a counter-movement and serve as a catalyst in the short term. The yellow line in the chart could be a short-term support. The black line in the chart: The starting price of the idea is $140.33. The red line in the chart: The stop-loss is $134 (GAP of October 11, 2017). The green line in the chart: This is in my opinion a possible first turning point in the idea = first target at about 145 US-Dollar (high October 23). The chart-based indicators such as RSI and MACD do not show a very positive picture, but a turnaround could be ushered in. Conclusion: Johnson & Johnson promises pure excitement! An entry into an idea is currently made and based on the fundamental data and the news! Stay on the pulse of this idea at nextmarkets.com. Parameters of the idea - Start Course Idea: $140.33 Recent price: $140.33 (+ 0.00% of starting price) Stop loss currently: $134 (-4.51% of starting price) Take Profit: $ 165 (highest short) This idea runs since today. Disclosure: “Both Wikifolio's, UMBRELLA (www.wikifolio.com) and FuTureUS (www.wikifolio.com ) can be invested in Panasonic Corporation. The trading ideas published here are neither to be understood as a recommendation nor as an offer or an invitation to buy or sell financial instruments and should not be understood as such. You must also assume that the author holds the recommended position in his portfolio and benefits from the implementation of his trading ideas.”
NYSE:JNJLong
by Ritschy
It's time! This idea is being spiced up now!As a reminder: Based on 17 analysts offering 12 month price targets for JNJ in the last 3 months: The average price target is $ 147 The maximum price target is $ 165 The lowest price target is $ 110 The entry into this idea is currently at $ 144.33. What say the technical analysis methods I use? The risk management tool used here is the own-developed “Traffic Signals System” (TSS) and it will be implemented in my future analyses. The yellow circle on the 11th of October in the chart indicates a possible break-away GAP for me. The 2nd yellow circle on October 30 in the chart could be closed in a counter-movement and serve as a catalyst in the short term. The yellow line in the chart could be a short-term support. The black line in the chart: The starting price of the idea is $140.33. The red line in the chart: The stop-loss is $134 (GAP of October 11, 2017). The green line in the chart: This is in my opinion a possible first turning point in the idea = first target at about 145 US-Dollar (high October 23). The chart-based indicators such as RSI and MACD do not show a very positive picture, but a turnaround could be ushered in. Conclusion: Johnson & Johnson promises pure excitement! An entry into an idea is currently made and based on the fundamental data and the news! Stay on the pulse of this idea at nextmarkets.com. Parameters of the idea - Start Course Idea: $140.33 Recent price: $140.33 (+ 0.00% of starting price) Stop loss currently: $134 (-4.51% of starting price) Take Profit: $ 165 (highest short) This idea runs since today. Disclosure: “Both Wikifolio's, UMBRELLA (www.wikifolio.com) and FuTureUS (www.wikifolio.com ) can be invested in Panasonic Corporation. The trading ideas published here are neither to be understood as a recommendation nor as an offer or an invitation to buy or sell financial instruments and should not be understood as such. You must also assume that the author holds the recommended position in his portfolio and benefits from the implementation of his trading ideas.”
NYSE:JNJLong
by Ritschy
Strong pharmaceutical growthJohnson & Johnson is an American multinational medical devices, pharmaceutical and consumer packaged goods manufacturing company. Includes more than 275 companies that sell its products in almost all countries of the world. Newsflow: Recently some good news for Johnson & Johnson!!! First of all, the Superior Court of California tossed the the record breaking cancer verdicts against J&J. This saves the company from a penalty payment up to 400 million US-Dollar. Secondly, the company reported on October 17, 2017 Third-Quarter Results. Sales of $19.7 Billion Increased 10.3% versus 2016. EPS was $1.37. Adjusted Third-Quarter EPS of $1.90 increased 13.1%. Based on 17 analysts offering 12 month price targets for JNJ in the last 3 months: The average price target of 147 US-Dollar The maximum price target of 165 US-Dollar The lowest price target of 110 US-Dollar Today J&J’s stock price is about 142 US-Dollar a share. Fundamental Data: P/E ratio: 23.57 / Sales growth: 2.59% / Profit growth: 7.34% / Dividend: $3.15/2.21% (Source: teletrader). Chart Tools: What say the technical analysis methods I use? Oscillator: The RSI of Johnson&Johnson breaks the overbought line and still forwarding in an upward direction. I consider this situation in short-term as slightly negative or neutral. Trend indicator: In the chart with the yellow eclipse was marked the situation, when the MACD line crosses to the upside of the 9 EMA and that was a bullish opportunity setting up. MACD of Johnson&Johnson is still in the positive zone and rises above the 9-period EMA line and indicates an upward trend. CONCLUSION: Johnson & Johnson won on a court issue and saved 400 million US-Dollar !!! Further, the company accelerated growth in the third quarter. This is driven by the strong performance of the Pharmaceutical business, and augmented by Actelion and other recent acquisitions across the enterprise that will continue to fuel growth, said Alex Gorsky, Chairman and Chief Executive Officer. The fundamental growth of Johnson&Johnson is impressive! Chart-based indicators as RSI and MACD show more negative picture, because they both indicate an overbought situation for short-term traders. Johnson & Johnson promises pure tension! An entry into a position-trade will be evaluated in the next few days depending on the chart situation! Stay tuned for updates! Disclosure: “The trading ideas published here are neither to be understood as a recommendation nor as an offer or an invitation to buy or sell financial instruments and should not be understood as such. You must also assume that the author holds the recommended position in his portfolio and benefits from the implementation of his trading ideas.”
NYSE:JNJ
by Ritschy
October 17 Earnings: Johnson&Johnson- Generic Competition GaloreJohnson & Johnson has been on an impressive intra-quarterly run with solid performance across major segments. Strengths in the company's performance are to be driven by: -Imbruvica and Darzalex should continue to perform well. Meaningful improvement from Stelara and Xarelto. -New product launches like Tremfy (approved in the US late 2017 for plaque psoriasis) -Revenue contribution from Swiss biotech Actelion, which J&J bought in June. -Medical devices segment is expected to continue its strong growth trajectory with new product launches. Weaknesses for the quarter are expected to be: -Key arthritis drug Remicade to remain under pressure from generic competition. -Invokana hurting from higher managed care discounting. -Sluggish FDA review requiring more information before approving new drug treatments. -Lawsuit from Pfizer to be clarified during the conference call. Overall, I believe high expenses and generic competition will overcome the positives for the quarter. I'm starting Johnson&Johnson with a $130 PT for the post earnings move with a tight but flexible 2.5% stop.
NYSE:JNJShort
by TraderDanER